What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Osteoporosis
His primary areas of investigation include Osteoporosis, Bone mineral, Internal medicine, Bone remodeling and Urology.
His Osteoporosis study combines topics in areas such as Placebo and Surgery.
His work in Bone mineral covers topics such as Dentistry which are related to areas like Risedronate Sodium, Hip bone, Observational study and Medical laboratory.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology and Physical therapy.
His work deals with themes such as Randomized controlled trial and Bone resorption, which intersect with Bone remodeling.
His work carried out in the field of Bone density brings together such families of science as Postmenopausal women and Denosumab.
His most cited work include:
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis (2129 citations)
- Primer on the metabolic bone diseases and disorders of mineral metabolism (1854 citations)
- Effect of Risedronate on the Risk of Hip Fracture in Elderly Women (1701 citations)
What are the main themes of his work throughout his whole career to date?
Michael R. McClung spends much of his time researching Osteoporosis, Internal medicine, Bone mineral, Bone density and Endocrinology.
His biological study spans a wide range of topics, including Placebo, Surgery, Bone remodeling and Urology.
His Surgery study incorporates themes from Ibandronic acid, Bisphosphonate, Tolerability and Hip fracture.
He focuses mostly in the field of Bone mineral, narrowing it down to matters related to Femoral neck and, in some cases, Risedronic acid and Adverse effect.
His Bone density research includes elements of Physical therapy, Menopause, Nuclear medicine and Risk factor.
In general Endocrinology, his work in Alendronic acid is often linked to Context linking many areas of study.
He most often published in these fields:
- Osteoporosis (61.60%)
- Internal medicine (40.40%)
- Bone mineral (40.80%)
What were the highlights of his more recent work (between 2014-2021)?
- Osteoporosis (61.60%)
- Internal medicine (40.40%)
- Bone mineral (40.80%)
In recent papers he was focusing on the following fields of study:
Michael R. McClung mainly investigates Osteoporosis, Internal medicine, Bone mineral, Denosumab and Placebo.
The study incorporates disciplines such as Physical therapy, Incidence and Bone remodeling in addition to Osteoporosis.
His Internal medicine research incorporates themes from Endocrinology and Oncology.
His study in Bone mineral is interdisciplinary in nature, drawing from both Urology, Post-hoc analysis, Prospective cohort study, Parathyroid hormone and Cohort.
His studies deal with areas such as Discontinuation and Osteonecrosis of the jaw as well as Denosumab.
His Placebo research incorporates elements of Femur, Surgery, Phases of clinical research, Meta-analysis and Lumbar vertebrae.
Between 2014 and 2021, his most popular works were:
- The 2017 hormone therapy position statement of The North American Menopause Society. (467 citations)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016--EXECUTIVE SUMMARY (412 citations)
- Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension (224 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
